Answers are grounded in this paper and cite their sources.
This analysis uncovers the role of CDKN2A variants in poor outcomes in extramammary Paget disease, suggesting clinical significance.
Background: Several studies have described the mutational landscape of extramammary Paget disease (EMPD), including CDKN2A loss as a common genetic alteration. However, the prognostic implications of genetic alterations remain largely unexplored. Although CDKN2A loss is associated with tumor progression or poor prognosis in some types of cancer, its clinical significance in EMPD has not been well investigated.
No takes yet. Share an insight, caveat, or question.
Iwasawa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: